Study of Remimazolam Tosilate in Patients Undergoing Colonoscopy
A Phase Ⅲ, Multicentre, Randomized, Single-blinded Study to Evaluate the Safety and Efficacy of the Sedation for Remimazolam or Propofol in Patients Undergoing Colonoscopy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 010
- Clinical trial Ethnics Committee of Peking Union Medical College Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- subjects aged 18-65 years;
- intending to undergo colonoscopy;
- ASA( American Society of Anesthesiologists) I or II;
- 18 kg/m²<BMI(Body Mass Index)<30 kg/m²;
- the operation time of gastroscopy is not more than 30 min;
- Signed informed consent.
Exclusion Criteria:
Patients need to be Complicated colonoscopy;
- Patients need to be Tracheal intubation;
- Patients with respiratory management difficulties (Modified Mallampati grade IV);
- one or more of the laboratory findings fall out of the limitations for this study(platelet,hemoglobin,aspartate aminotransferase,etc.);
- A history of drug abuse and / or alcohol abuse 2 years prior to the screening period;
- allergic to drugs used in the study;
- pregnant women or those in lactation period
- The subject has participated in other clinical trial within the 3 months prior to randomization.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Propofol
|
Initial dose plus supplemental doses as necessary
|
|
Experimental: Remimazolam Tosilate
|
Initial dose plus supplemental doses as necessary
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
rate of successful sedation
Time Frame: approximately 3 hours
|
successful sedation rate as measured by the proportion of subjects who experienced successful sedation during colonoscopy
|
approximately 3 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sedation induction time
Time Frame: approximately 3 hours
|
Sedation induction time is defined as from start of study drug injection to the first time of MOAA/S(The Observer's Assessment of Alertness/Sedation Scale) ≤ 3.
|
approximately 3 hours
|
|
Sedation recovery time
Time Frame: approximately 3 hours
|
Sedation induction time is defined as from stop of study drug injection to be wide awake.
|
approximately 3 hours
|
|
rate of hypotension
Time Frame: approximately 3 hours
|
rate of hypotension as measured by the proportion of subjects who experienced hypotension
|
approximately 3 hours
|
|
rate of respiratory depression
Time Frame: approximately 3 hours
|
rate of respiratory depression as measured by the proportion of subjects who experienced respiratory depression
|
approximately 3 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HR-RMZL-Ⅲ-PEC
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.